EVAXION_DEEPBLUE_RGB.png
Evaxion announces closing of $10.8 million public offering
January 31, 2025 16:05 ET | Evaxion Biotech
COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...
EVAXION_DEEPBLUE_RGB.png
Evaxion announces pricing of $10.8 million public offering
January 30, 2025 08:00 ET | Evaxion Biotech
COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...
EVAXION_DEEPBLUE_RGB.png
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
January 28, 2025 08:15 ET | Evaxion Biotech
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirementEvaxion has currently restored its...
EVAXION_DEEPBLUE_RGB.png
Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01
January 15, 2025 08:00 ET | Evaxion Biotech
Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio...
EVAXION_DEEPBLUE_RGB.png
Evaxion announces completion of ADS ratio change
January 14, 2025 16:05 ET | Evaxion Biotech
COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines,...
EVAXION_DEEPBLUE_RGB.png
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
January 10, 2025 08:00 ET | Evaxion Biotech
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced...
EVAXION_DEEPBLUE_RGB.png
Evaxion announces plan to implement ADS ratio change
December 30, 2024 08:00 ET | Evaxion Biotech
COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced...
EVAXION_DEEPBLUE_RGB.png
Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity
December 17, 2024 08:00 ET | Evaxion Biotech
Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion’s €7 million loan with EIB into an equity-type instrumentSuch conversion is...
EVAXION_DEEPBLUE_RGB.png
Evaxion establishes new AI-derived precision cancer vaccine concept
December 12, 2024 08:00 ET | Evaxion Biotech
Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical data confirms the...
EVAXION_DEEPBLUE_RGB.png
Evaxion announces 2025 milestones reflecting continued strong strategy execution
December 09, 2024 08:00 ET | Evaxion Biotech
With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones reflect all parts of Evaxion’s strategy for value...